{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:43:31Z","timestamp":1790739811393,"version":"4.1.0"},"reference-count":94,"publisher":"SAGE Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPD"],"published-print":{"date-parts":[[2021,8,2]]},"abstract":"<jats:p>Background: The gold-standard treatment for Parkinson\u2019s disease is L-DOPA, which in the long term often leads to levodopa-induced dyskinesia. Serotonergic neurons are partially responsible for this, by converting L-DOPA into dopamine leading to its uncontrolled release as a \u201cfalse neurotransmitter\u201d. The stimulation of 5-HT1A receptors can reduce involuntary movements but this mechanism is poorly understood. Objective: This study aimed to investigate the functionality of 5-HT1A receptors using positron emission tomography in hemiparkinsonian rats with or without dyskinesia induced by 3-weeks daily treatment with L-DOPA. Imaging sessions were performed \u201coff\u201d L-DOPA. Methods: Each rat underwent a positron emission tomography scan with [18F]F13640, a 5-HT1AR agonist which labels receptors in a high affinity state for agonists, or with [18F]MPPF, a 5-HT1AR antagonist which labels all the receptors. Results: There were decreases of [18F]MPPF binding in hemiparkinsonian rats in cortical areas. In dyskinetic animals, changes were slighter but also found in other regions. In hemiparkinsonian rats, [18F]F13640 uptake was decreased bilaterally in the globus pallidus and thalamus. On the non-lesioned side, binding was increased in the insula, the hippocampus and the amygdala. In dyskinetic animals, [18F]F13640 binding was strongly increased in cortical and limbic areas, especially in the non-lesioned side. Conclusion: These data suggest that agonist and antagonist 5-HT1A receptor-binding sites are differently modified in Parkinson\u2019s disease and levodopa-induced dyskinesia. In particular, these observations suggest a substantial involvement of the functional state of 5-HT1AR in levodopa-induced dyskinesia and emphasize the need to characterize this state using agonist radiotracers in physiological and pathological conditions.<\/jats:p>","DOI":"10.3233\/jpd-212580","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T14:12:23Z","timestamp":1620742343000},"page":"1257-1269","source":"Crossref","is-referenced-by-count":7,"title":["Different Alterations of Agonist and Antagonist Binding to 5-HT1A Receptor in a Rat Model of Parkinson\u2019s Disease and Levodopa-Induced Dyskinesia: A MicroPET Study"],"prefix":"10.1177","volume":"11","author":[{"given":"Benjamin","family":"Vidal","sequence":"first","affiliation":[{"name":"Lyon Neuroscience Research Center, Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon 1, CNRS, INSERM, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Levigoureux","sequence":"additional","affiliation":[{"name":"Lyon Neuroscience Research Center, Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon 1, CNRS, INSERM, Lyon, France"},{"name":"Hospices Civils de Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Chaib","sequence":"additional","affiliation":[{"name":"Lyon Neuroscience Research Center, Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon 1, CNRS, INSERM, Lyon, France"},{"name":"Hospices Civils de Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Bouillot","sequence":"additional","affiliation":[{"name":"CERMEP-Imaging Platform, Bron, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Billard","sequence":"additional","affiliation":[{"name":"CERMEP-Imaging Platform, Bron, France"},{"name":"Institute of Chemistry and Biochemistry, Universit\u00e9 de Lyon, CNRS, Villeurbanne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Newman-Tancredi","sequence":"additional","affiliation":[{"name":"Neurolixis SAS, Castres, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Zimmer","sequence":"additional","affiliation":[{"name":"Lyon Neuroscience Research Center, Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon 1, CNRS, INSERM, Lyon, France"},{"name":"Hospices Civils de Lyon, Lyon, France"},{"name":"CERMEP-Imaging Platform, Bron, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JPD-212580_ref1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","article-title":"Epidemiology of Parkinson\u2019s disease","volume":"5","author":"de Lau","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.3233\/JPD-212580_ref2","first-page":"56","article-title":"How do you treat motor complications in Parkinson\u2019s disease: Medicine, surgery, or both?S","volume":"64 Suppl 2","author":"Fahn","year":"2008","journal-title":"Ann Neurol"},{"key":"10.3233\/JPD-212580_ref3","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.3233\/JPD-212580_ref4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2217\/nmt-2017-0027","article-title":"Parkinson\u2019s disease and the quest for preclinical diagnosis: An interview with Professor Werner Poewe","volume":"7","author":"Poewe","year":"2017","journal-title":"Neurodegener Dis Manag"},{"key":"10.3233\/JPD-212580_ref5","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/S0140-6736(17)32101-3","article-title":"Insulin signalling: New target for Parkinson\u2019s treatments?","volume":"390","author":"Poewe","year":"2017","journal-title":"Lancet"},{"key":"10.3233\/JPD-212580_ref6","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(77)91146-1","article-title":"Success and problems of long-term levodopa therapy in Parkinson\u2019s disease","volume":"1","author":"Marsden","year":"1977","journal-title":"Lancet"},{"key":"10.3233\/JPD-212580_ref7","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.bbr.2014.07.037","article-title":"Serotonin in Parkinson\u2019s disease","volume":"277","author":"Politis","year":"2015","journal-title":"Behav Brain Res"},{"key":"10.3233\/JPD-212580_ref8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.pneurobio.2015.09.005","article-title":"New insight into the therapeutic role of the serotonergic system in Parkinson\u2019s disease","volume":"134","author":"Ohno","year":"2015","journal-title":"Prog Neurobiol"},{"key":"10.3233\/JPD-212580_ref9","first-page":"439","article-title":"Dampening of serotonergic system through 5HT1A receptors is a promising target for treatment of levodopa induced motor problems","volume":"3","author":"Mahmoudi","year":"2013","journal-title":"Adv Pharm Bull"},{"key":"10.3233\/JPD-212580_ref10","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats","volume":"130","author":"Carta","year":"2007","journal-title":"Brain"},{"key":"10.3233\/JPD-212580_ref11","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3389\/fneur.2014.00242","article-title":"Presynaptic mechanisms of l-DOPA-induced dyskinesia: The findings, the debate, and the therapeutic implications","volume":"5","author":"Cenci","year":"2014","journal-title":"Front Neurol"},{"key":"10.3233\/JPD-212580_ref12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2217\/nmt-2016-0005","article-title":"Nondopaminergic treatments for Parkinson\u2019s disease: Current and future prospects","volume":"6","author":"Freitas","year":"2016","journal-title":"Neurodegener Dis Manag"},{"key":"10.3233\/JPD-212580_ref13","first-page":"268","article-title":"Serotonergic system modulation holds promise for L-DOPA-induced dyskinesias in hemiparkinsonian rats: A systematic review","volume":"19","author":"Farajdokht","year":"2020","journal-title":"EXCLI J"},{"key":"10.3233\/JPD-212580_ref14","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.expneurol.2015.05.021","article-title":"NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat","volume":"271","author":"Iderberg","year":"2015","journal-title":"Exp Neurol"},{"key":"10.3233\/JPD-212580_ref15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.neuropharm.2015.02.023","article-title":"Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson\u2019s disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist","volume":"95","author":"Iderberg","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.3233\/JPD-212580_ref16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.neuropharm.2015.01.012","article-title":"Activity of serotonin 5-HT(1A) receptor \u2018biased agonists\u2019 in rat models of Parkinson\u2019s disease and L-DOPA-induced dyskinesia","volume":"93","author":"Iderberg","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.3233\/JPD-212580_ref17","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/jnr.21978","article-title":"Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats","volume":"87","author":"Bishop","year":"2009","journal-title":"J Neurosci Res"},{"key":"10.3233\/JPD-212580_ref18","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.expneurol.2017.03.013","article-title":"Characterizing the differential roles of striatal 5-HT1A auto- and hetero-receptors in the reduction of l-DOPA-induced dyskinesia","volume":"292","author":"Meadows","year":"2017","journal-title":"Exp Neurol"},{"key":"10.3233\/JPD-212580_ref19","first-page":"1","article-title":"Improving the treatment of Parkinson\u2019s disease: A novel approach by modulating 5-HT(1A) receptors","volume":"4","author":"Shimizu","year":"2013","journal-title":"Aging Dis"},{"key":"10.3233\/JPD-212580_ref20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/bs.irn.2018.08.002","article-title":"Molecular imaging of the serotonergic system in Parkinson\u2019s disease","volume":"141","author":"Pagano","year":"2018","journal-title":"Int Rev Neurobiol"},{"key":"10.3233\/JPD-212580_ref21","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/mds.24964","article-title":"Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson\u2019s disease","volume":"27","author":"Huot","year":"2012","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-212580_ref22","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1016\/j.neurobiolaging.2010.09.011","article-title":"Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque","volume":"33","author":"Huot","year":"2012","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JPD-212580_ref23","first-page":"e209","article-title":"Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque","volume":"33","author":"Huot P,","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JPD-212580_ref24","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1212\/01.WNL.0000031424.51127.2B","article-title":"Tremor in Parkinson\u2019s disease and serotonergic dysfunction: An 11C-WAY 100635 PET study","volume":"60","author":"Doder","year":"2003","journal-title":"Neurology"},{"key":"10.3233\/JPD-212580_ref25","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1212\/WNL.0000000000001909","article-title":"Putaminal serotonergic innervation: Monitoring dyskinesia risk in Parkinson disease","volume":"85","author":"Lee","year":"2015","journal-title":"Neurology"},{"key":"10.3233\/JPD-212580_ref26","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/mds.23895","article-title":"Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson\u2019s disease","volume":"27","author":"Ballanger","year":"2012","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-212580_ref27","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0006-8993(92)91100-S","article-title":"Further evidence for differential affinity states of the serotonin1A receptor in rat hippocampus","volume":"590","author":"Mongeau","year":"1992","journal-title":"Brain Res"},{"key":"10.3233\/JPD-212580_ref28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0922-4106(95)90192-2","article-title":"The selective 5-HT1A antagonist radioligand [3H]WAY 100635 labels both G-protein-coupled and free 5-HT1A receptors in rat brain membranes","volume":"288","author":"Gozlan","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.3233\/JPD-212580_ref29","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jchemneu.2006.01.006","article-title":"A comparison of in vivo and in vitro neuroimaging of 5-HT 1A receptor binding sites in the cat brain","volume":"31","author":"Aznavour","year":"2006","journal-title":"J Chem Neuroanat"},{"key":"10.3233\/JPD-212580_ref30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cca.2005.11.003","article-title":"The involvement of G proteins and regulators of receptor-G protein coupling in the pathophysiology, diagnosis and treatment of mood disorders","volume":"366","author":"Avissar","year":"2006","journal-title":"Clin Chim Acta"},{"key":"10.3233\/JPD-212580_ref31","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/cns.12306","article-title":"A postmortem study to compare agonist and antagonist 5-HT1A receptor-binding sites in Alzheimer\u2019s disease","volume":"20","author":"Becker","year":"2014","journal-title":"CNS Neurosci Ther"},{"key":"10.3233\/JPD-212580_ref32","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.neuropharm.2016.05.009","article-title":"Agonist and antagonist bind differently to 5-HT1A receptors during Alzheimer\u2019s disease: A post-mortem study with PET radiopharmaceuticals","volume":"109","author":"Vidal","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.3233\/JPD-212580_ref33","doi-asserted-by":"crossref","first-page":"80111","DOI":"10.18632\/oncotarget.13418","article-title":"Pharmacological agonists for more-targeted CNS radio-pharmaceuticals","volume":"7","author":"Zimmer","year":"2016","journal-title":"Oncotarget"},{"key":"10.3233\/JPD-212580_ref34","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1007\/s00429-018-1672-7","article-title":". 18F-F13640 preclinical evaluation in rodent, cat and primate as a 5-HT1A receptor agonist for PET neuroimaging","volume":"223","author":"Vidal","year":"2018","journal-title":"Brain Struct Funct"},{"key":"10.3233\/JPD-212580_ref35","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s00259-019-04473-7","article-title":"(18)F-F13640 PET imaging of functional receptors in humans","volume":"47","author":"Colom","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.3233\/JPD-212580_ref36","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0028-3908(02)00119-3","article-title":"Large-amplitude 5-HT1A receptor activation: A new mechanism of profound, central analgesia","volume":"43","author":"Colpaert","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.3233\/JPD-212580_ref37","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/jphp.12762","article-title":"Distinctive in vitro signal transduction profile of NLX-112, a potent and efficacious serotonin 5-HT1A receptor agonist","volume":"69","author":"Newman-Tancredi","year":"2017","journal-title":"J Pharm Pharmacol"},{"key":"10.3233\/JPD-212580_ref38","unstructured":"Paxinos G , Watson C (2013) The Rat Brain in Stereotaxic Coordinates. Academic Press"},{"key":"10.3233\/JPD-212580_ref39","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0006-8993(93)90576-9","article-title":"Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats","volume":"626","author":"Hudson","year":"1993","journal-title":"Brain Res"},{"key":"10.3233\/JPD-212580_ref40","doi-asserted-by":"crossref","first-page":"e109113","DOI":"10.1371\/journal.pone.0109113","article-title":"A multi-atlas based method for automated anatomical rat brain MRI segmentation and extraction of PET activity","volume":"9","author":"Lancelot","year":"2014","journal-title":"PLoS One"},{"key":"10.3233\/JPD-212580_ref41","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1097\/00004647-199609000-00008","article-title":"Distribution volume ratios without blood sampling from graphical analysis of PET data","volume":"16","author":"Logan","year":"1996","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.3233\/JPD-212580_ref42","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/bs.irn.2019.06.013","article-title":"Dysfunction of serotonergic neurons in Parkinson\u2019s disease and dyskinesia","volume":"146","author":"Vegas-Suarez","year":"2019","journal-title":"Int Rev Neurobiol"},{"key":"10.3233\/JPD-212580_ref43","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/bs.irn.2017.05.002","article-title":"Cognition in Parkinson\u2019s disease","volume":"133","author":"O\u2019Callaghan","year":"2017","journal-title":"Int Rev Neurobiol"},{"key":"10.3233\/JPD-212580_ref44","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.nbd.2011.12.041","article-title":"Psychosis, apathy, depression and anxiety in Parkinson\u2019s disease","volume":"46","author":"Gallagher","year":"2012","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JPD-212580_ref45","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s00702-018-1865-5","article-title":"The serotonergic system in L-DOPA-induced dyskinesia: Pre-clinical evidence and clinical perspective","volume":"125","author":"Carta","year":"2018","journal-title":"J Neural Transm (Vienna)"},{"key":"10.3233\/JPD-212580_ref46","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3390\/ijms21010294","article-title":"L-DOPA in Parkinson\u2019s disease: Looking at the \u201cfalse\u201d neurotransmitters and their meaning","volume":"21","author":"Chagraoui","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.3233\/JPD-212580_ref47","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1212\/WNL.57.10.1829","article-title":"Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models","volume":"57","author":"Bibbiani","year":"2001","journal-title":"Neurology"},{"key":"10.3233\/JPD-212580_ref48","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.nbd.2006.02.003","article-title":"5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson\u2019s disease","volume":"23","author":"Bezard","year":"2006","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JPD-212580_ref49","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00213-006-0680-0","article-title":"Postsynaptic 5-HT1A receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: Implications for treating Parkinson\u2019s disease","volume":"192","author":"Mignon","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"10.3233\/JPD-212580_ref50","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.brainres.2006.07.003","article-title":"Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions","volume":"1112","author":"Matsubara","year":"2006","journal-title":"Brain Res"},{"key":"10.3233\/JPD-212580_ref51","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.euroneuro.2010.04.005","article-title":"F15599, a preferential post-synaptic 5-HT1A receptor agonist: Activity in models of cognition in comparison with reference 5-HT1A receptor agonists","volume":"20","author":"Depoortere","year":"2010","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.3233\/JPD-212580_ref52","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.neuroscience.2014.03.033","article-title":"Activation of prelimbic 5-HT1A receptors produces antidepressant-like effects in a unilateral rat model of Parkinson\u2019s disease","volume":"268","author":"Hui","year":"2014","journal-title":"Neuroscience"},{"key":"10.3233\/JPD-212580_ref53","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bbr.2014.04.053","article-title":"Anxiolytic effects of prelimbic 5-HT(1A) receptor activation in the hemiparkinsonian rat","volume":"277","author":"Hui","year":"2015","journal-title":"Behav Brain Res"},{"key":"10.3233\/JPD-212580_ref54","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.neuropharm.2015.03.007","article-title":"Activation of 5-HT(1)A receptors in the medial subdivision of the central nucleus of the amygdala produces anxiolytic effects in a rat model of Parkinson\u2019s disease","volume":"95","author":"Sun","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.3233\/JPD-212580_ref55","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000505212","article-title":"Involvement of the dorsal hippocampus 5-HT1A receptors in the regulation of depressive-like behaviors in hemiparkinsonian rats","volume":"79","author":"Jiang","year":"2020","journal-title":"Neuropsychobiology"},{"key":"10.3233\/JPD-212580_ref56","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1021\/acschemneuro.6b00440","article-title":"Serotonergic approaches in Parkinson\u2019s disease: Translational perspectives, an update","volume":"8","author":"Huot","year":"2017","journal-title":"ACS Chem Neurosci"},{"key":"10.3233\/JPD-212580_ref57","doi-asserted-by":"crossref","first-page":"107997","DOI":"10.1016\/j.neuropharm.2020.107997","article-title":"The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets","volume":"167","author":"Fisher","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.3233\/JPD-212580_ref58","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s11064-018-2514-y","article-title":"Effects of the serotonin 5-HT1A receptor biased agonists, F13714 and F15599, on striatal neurotransmitter levels following L-DOPA administration in hemi-parkinsonian rats","volume":"43","author":"Newman-Tancredi","year":"2018","journal-title":"Neurochem Res"},{"key":"10.3233\/JPD-212580_ref59","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.neuropharm.2016.01.013","article-title":"The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements","volume":"105","author":"McCreary","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.3233\/JPD-212580_ref60","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1021\/cn300234z","article-title":"Effects of 5-HT1A receptor stimulation on D1 receptor agonist-induced striatonigral activity and dyskinesia in hemiparkinsonian rats","volume":"4","author":"Dupre","year":"2013","journal-title":"ACS Chem Neurosci"},{"key":"10.3233\/JPD-212580_ref61","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/bph.12894","article-title":"Side effect profile of 5-HT treatments for Parkinson\u2019s disease and L-DOPA-induced dyskinesia in rats","volume":"172","author":"Lindenbach","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.3233\/JPD-212580_ref62","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.neuropharm.2008.08.031","article-title":"Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat","volume":"55","author":"Dupre","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.3233\/JPD-212580_ref63","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1124\/jpet.106.110429","article-title":"In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with increased motor disability","volume":"319","author":"Iravani","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.3233\/JPD-212580_ref64","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.neures.2013.10.002","article-title":"Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia","volume":"77","author":"Bezard","year":"2013","journal-title":"Neurosci Res"},{"key":"10.3233\/JPD-212580_ref65","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/mds.25366","article-title":"Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia","volume":"28","author":"Bezard","year":"2013","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-212580_ref66","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/mds.20370","article-title":"Effects of serotonin 5-HT1A agonist in advanced Parkinson\u2019s disease","volume":"20","author":"Bara-Jimenez","year":"2005","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-212580_ref67","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/mds.21226","article-title":"Sarizotan as a treatment for dyskinesias in Parkinson\u2019s disease: A double-blind placebo-controlled trial","volume":"22","author":"Goetz","year":"2007","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-212580_ref68","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/mds.20243","article-title":"Levodopa in the treatment of Parkinson\u2019s disease: Current controversies","volume":"19","author":"Olanow","year":"2004","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-212580_ref69","first-page":"133","article-title":"[Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson\u2019s disease]","volume":"54","author":"Kannari","year":"2002","journal-title":"No To Shinkei"},{"key":"10.3233\/JPD-212580_ref70","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3389\/fnmol.2019.00255","article-title":"Is there a role for GPCR agonist radiotracers in PET neuroimaging?","volume":"12","author":"Colom","year":"2019","journal-title":"Front Mol Neurosci"},{"key":"10.3233\/JPD-212580_ref71","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/med.21552","article-title":"Hunting for the high-affinity state of G-protein-coupled receptors with agonist tracers: Theoretical and practical considerations for positron emission tomography imaging","volume":"39","author":"Shalgunov","year":"2019","journal-title":"Med Res Rev"},{"key":"10.3233\/JPD-212580_ref72","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/00004647-200003000-00001","article-title":"Imaging synaptic neurotransmission with in vivo binding competition techniques: A critical review","volume":"20","author":"Laruelle","year":"2000","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.3233\/JPD-212580_ref73","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1038\/jcbfm.2010.104","article-title":"Measuring endogenous 5-HT release by emission tomography: Promises and pitfalls","volume":"30","author":"Paterson","year":"2010","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.3233\/JPD-212580_ref74","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.apradiso.2015.10.004","article-title":"Optimal timing of [(1)(8)F]Mefway PET for imaging the serotonin 1A receptor in healthy male subjects","volume":"107","author":"Lee","year":"2016","journal-title":"Appl Radiat Isot"},{"key":"10.3233\/JPD-212580_ref75","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/syn.21834","article-title":"Relationship between dopamine deficit and the expression of depressive behavior resulted from alteration of serotonin system","volume":"69","author":"Lee","year":"2015","journal-title":"Synapse"},{"key":"10.3233\/JPD-212580_ref76","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3389\/fncel.2017.00274","article-title":"Impairment of serotonergic transmission by the antiparkinsonian drug L-DOPA: Mechanisms and clinical implications","volume":"11","author":"Miguelez","year":"2017","journal-title":"Front Cell Neurosci"},{"key":"10.3233\/JPD-212580_ref77","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0014-2999(99)00738-4","article-title":"Correlation between low\/high affinity ratios for 5-HT(1A) receptors and intrinsic activity","volume":"386","author":"Assie","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"10.3233\/JPD-212580_ref78","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fnana.2018.00038","article-title":"Evidence for sprouting of dopamine and serotonin axons in the pallidum of parkinsonian monkeys","volume":"12","author":"Gagnon","year":"2018","journal-title":"Front Neuroanat"},{"key":"10.3233\/JPD-212580_ref79","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15437"},{"key":"10.3233\/JPD-212580_ref80","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/bs.irn.2017.02.015","article-title":"Imaging in Parkinson\u2019s disease","volume":"132","author":"Politis","year":"2017","journal-title":"Int Rev Neurobiol"},{"key":"10.3233\/JPD-212580_ref81","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.nbd.2010.01.012","article-title":"Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson\u2019s disease","volume":"38","author":"Navailles","year":"2010","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JPD-212580_ref82","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.nbd.2010.11.007","article-title":"Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson\u2019s disease","volume":"41","author":"Navailles","year":"2011","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JPD-212580_ref83","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1007\/s00213-015-3980-4","article-title":"Behavioral impairments and serotonin reductions in rats after chronic L-dopa","volume":"232","author":"Stansley","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"10.3233\/JPD-212580_ref84","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s10571-007-9213-6","article-title":"Long-term L-DOPA treatment causes indiscriminate increase in dopamine levels at the cost of serotonin synthesis in discrete brain regions of rats","volume":"27","author":"Borah","year":"2007","journal-title":"Cell Mol Neurobiol"},{"key":"10.3233\/JPD-212580_ref85","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1124\/jpet.114.218966","article-title":"Chronic L-dopa decreases serotonin neurons in a subregion of the dorsal raphe nucleus","volume":"351","author":"Stansley","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.3233\/JPD-212580_ref86","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1111\/j.1471-4159.2009.06556.x","article-title":"L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson\u2019s disease: Temporal and quantitative relationship to the expression of dyskinesia","volume":"112","author":"Lindgren","year":"2010","journal-title":"J Neurochem"},{"key":"10.3233\/JPD-212580_ref87","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0149-7634(96)00032-2","article-title":"Dopamine and glutamate control each other\u2019s release in the basal ganglia: A microdialysis study of the entopeduncular nucleus and substantia nigra","volume":"21","author":"Biggs","year":"1997","journal-title":"Neurosci Biobehav Rev"},{"key":"10.3233\/JPD-212580_ref88","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.neubiorev.2010.06.007","article-title":"Potential mechanisms underlying anxiety and depression in Parkinson\u2019s disease: Consequences of l-DOPA treatment","volume":"35","author":"Eskow Jaunarajs","year":"2011","journal-title":"Neurosci Biobehav Rev"},{"key":"10.3233\/JPD-212580_ref89","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/ana.22097","article-title":"Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia","volume":"68","author":"Rylander","year":"2010","journal-title":"Ann Neurol"},{"key":"10.3233\/JPD-212580_ref90","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1177\/026988110401800304","article-title":"A positron emission tomography study of the 5-HT1A receptor in schizophrenia and during clozapine treatment","volume":"18","author":"Bantick","year":"2004","journal-title":"J Psychopharmacol"},{"key":"10.3233\/JPD-212580_ref91","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/sj.npp.1300390","article-title":"Occupancy of agonist drugs at the 5-HT1A receptor","volume":"29","author":"Bantick","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.3233\/JPD-212580_ref92","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1124\/jpet.301.3.1144","article-title":"5-Hydroxytryptamine1A receptor occupancy by novel full antagonist 2-[4-4-(7-chloro-2,3-dihydro-1,4-benzdioxyn-5-yl)-1-piperazinyl]butyl]-1,2-benzi sothiazol-3-(2H)-one-1,1-dioxide: a[11C][O-methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide trihydrochloride (WAY-100635) positron emission tomography study in humans","volume":"301","author":"Rabiner","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.3233\/JPD-212580_ref93","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1006\/nimg.2001.0984","article-title":"A database of [(11)C]WAY-100635 binding to 5-HT(1A) receptors in normal male volunteers: Normative data and relationship to methodological, demographic, physiological, and behavioral variables","volume":"15","author":"Rabiner","year":"2002","journal-title":"Neuroimage"},{"key":"10.3233\/JPD-212580_ref94","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/026988110201600301","article-title":"Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: A human PET study with [11C]WAY-100635 and [11C]raclopride","volume":"16","author":"Rabiner","year":"2002","journal-title":"J Psychopharmacol"}],"container-title":["Journal of Parkinson's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JPD-212580","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:49:56Z","timestamp":1777610996000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JPD-212580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,2]]},"references-count":94,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/jpd-212580","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,2]]}}}